We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 118

Mylan Pharmaceuticals ULC v. Pfizer Canada Inc., 2012 FCA 103 - Aricept (donepezil), appeal of NOC case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 3 2012

The Court of Appeal upheld on Order prohibiting the Minister of Health from issuing a NOC to Mylan for donepezil, a drug for the treatment of Alzheimer's type dementia, until expiry of Pfizer’s ‘808 Patent

Northern exposure?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • April 4 2013

Davit Akman and John Norman suggest that a recently commenced investigation into alleged "product switching" and statements by the Interim

English courts will take jurisdiction for infringement of foreign patents!

  • Gowling Lafleur Henderson LLP
  • -
  • United Kingdom
  • -
  • March 25 2013

In conjoined cases: Actavis Group hf v Eli Lilly & Company (USA)Medis ehf v Eli Lilly & Company (USA) 2012 EWHC 3316 (Pat), Mr. Justice Arnold has

Patents and Canadian competition laws

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, USA
  • -
  • April 22 2013

In Canada, the Competition Act largely defers to the Patent Act. For example, the Act's abuse of dominance provision (s. 79 Canada's

The Supreme Court of Canada holds Pfizer’s Viagra patent invalid

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

In a cautionary tale to be heeded by patent drafters, the Supreme Court of Canada held that Pfizer's patent directed to sildenafil, better known as

Markush claims can pose a risk of patent invalidity

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

As patent law in Canada continues to evolve in significant ways, it is important to remind ourselves of cases from the past few years that continue to impact patent drafting today and to influence the validity of patents, especially pharmaceutical patents in Canada

Apotex Inc. v. H. Lundbeck AS (2011 FC 88), citalopram, T-575-04, January 26, 2011

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • March 15 2011

In an action for patent infringement and under s. 8 of the Patented Medicines (Notice of Compliance) Regulations regarding citalopram, Prothonotary Tabib granted Lundeck’s request for letters rogatory with respect of Matrix Laboratories Ltd

Methods of medical treatment and dosage claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada

MediaCAT scratches the Norwich Pharmacal Order

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, United Kingdom
  • -
  • June 8 2011

In MediaCAT v Adam et al, His Honour Judge Birss considered the appropriateness of the Norwich Pharmacal Order and when it should be used, as he noted that there is a potential difficulty with the Norwich Pharmacal process: In short the judge was concerned about the lack of safeguards on the use of information obtained under these orders

Teva Canada Limited v. Wyeth LLC, December 9, 2011, 2011 FC 1442, venlafaxine

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 23 2012

This was a successful motion by the defendants to dismiss the plaintiff’s action for s.8 damages following a recent decision by Hughes J. (2011 FC 1169) in which he held that the plaintiff Teva was not permitted to continue ratiopharm’s claim for s. 8 damages following their merger

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy